Isarna Therapeutics

Isarna Therapeutics is a biotechnology company focused on developing antisense oligonucleotide therapies to treat serious diseases, particularly those involving TGF-β signaling pathways. Founded in 1998 in Munich, Germany, Isarna Therapeutics is engaged in developing innovative therapies targeting TGF-β pathways. The company has conducted a total of 11 deals, with its most recent deal occurring on April 22, 2014, when it raised EUR 5. 5 million from investors including AT Newtec, Global Asset Fund, and MIG Capital, bringing the total amount raised to EUR 5.

5 million and the current company valuation to EUR 48. 618 mn. The CEO, Karl-Hermann Schlingensiepen, leads the firm with a focus on advancing their product pipeline. Isarna Therapeutics specializes in developing antisense oligonucleotide therapies, primarily targeting TGF-β signaling pathways.

Their lead product, ISTH0036, is in Phase 2a clinical trials focused on treating ophthalmological conditions, including neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Additionally, Isarna's portfolio aims to provide treatment options for fibrotic liver diseases such as non-alcoholic steatohepatitis (NASH) and various cancers. Their therapies are designed for healthcare providers and research institutions worldwide, with a particular emphasis on Europe and North America, where eye diseases and liver conditions pose significant clinical challenges. Isarna Therapeutics operates under a business model that emphasizes partnerships and collaborations with research institutions and pharmaceutical companies.

Revenue is generated through licensing agreements, clinical trial collaborations, and anticipated future product sales. The company engages directly with healthcare providers and institutions that utilize their antisense therapies in clinical environments. Flagship products like ISTH0036 are positioned for high-value transactions with clinical centers specializing in ophthalmology and oncology, with pricing structures often reflecting milestone payments throughout the drug development process. Isarna Therapeutics plans to utilize the EUR 5.

5 million raised in April 2014 to further advance their product pipeline, including new therapies currently in development. They aim to expand their market presence specifically in North America and Europe by enhancing collaborations with clinical centers specializing in their therapeutic areas. The company is focused on launching additional products targeting TGF-β pathways, with an emphasis on addressing unmet medical needs in both ophthalmology and liver diseases.